Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
In the UK mortality from malignant mesothelioma (MM) is likely to more than double over the next 20 years and despite advances in surgery, chemotherapy and radiation treatment the overall prognosis for patients remains poor. A number of scoring systems based on assessment of clinicopathological features of patients with the disease have been developed but the search continues for further prognostic indicators. Angiogenesis, tumour necrosis (TN), epidermal growth factor receptor (EGFR) expression, cyclooxygenase-2 (COX-2) and matrix metalloproteinases (MMPs) have been linked with poor prognosis in some types of solid tumour and their relevance as prognostic factors in malignant mesothelioma is examined in this paper.
O'Byrne
Kenneth J
KJ
Thoracic Oncology Research Groups, St James's Hospital, Dublin, Ireland. kobyrne@stJames.ie
Edwards
John G
JG
Waller
David A
DA
D014408:Biomarkers, Tumor / Q000032:analysis*; D051546:Cyclooxygenase 2; D066246:ErbB Receptors / Q000032:analysis / Q000096:biosynthesis; D006801:Humans; D007527:Isoenzymes / Q000032:analysis / Q000096:biosynthesis; D020782:Matrix Metalloproteinases / Q000032:analysis / Q000096:biosynthesis; D008565:Membrane Proteins; D008654:Mesothelioma / Q000473:pathology*; D009389:Neovascularization, Pathologic; D010997:Pleural Neoplasms / Q000473:pathology*; D011379:Prognosis; D011451:Prostaglandin-Endoperoxide Synthases / Q000032:analysis / Q000096:biosynthesis
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D066246:ErbB Receptors; D020782:Matrix Metalloproteinases